

DRUG AUTHORIZATION REQUEST FORM



COMPLETING YOUR FORM...

To ensure prompt processing of your request, please complete the following Drug Authorization Request Form in full. Note that there are sections that must be completed by you, the patient, and sections that must be completed by your prescriber. Once completed, submit the form to Entente Plus via your method of choice:

By email: drugspecial.autho@ententeplus.ca

By fax: 1-866-797-6483

By mail: Entente Plus, Drug Special Authorization Team,
P.O BOX 1606, Windsor ON N9A 6W1

Note that submission of an incomplete form may result in delays.

Your request will be reviewed and evaluated by our Drug Special Authorization Department who will share the results with you. Should you have any questions, call Entente Plus's Contact Centre at 1-800-361-9888.

OTHER DRUG COVERAGE...

If you are eligible for coverage by another plan (public or private), indicate that in Section 1B of the authorization form.

If you have provincial drug coverage, please ensure that your prescriber has applied for coverage under your primary provincial drug plan. The result of that application must be attached to the completed Special Authorization Request Form.

PRESCRIPTION DRUG SPECIAL AUTHORIZATION REQUEST FORM

Please note: Incomplete information may delay your request for processing.

SECTION 1A – PATIENT INFORMATION

First Name		Certificate ID	Employer Name
Last Name		Date of Birth (YYYY/MM/DD)	Email Address
Street Address			Telephone (Home)
City	Province	Postal Code	Telephone (Mobile)

SECTION 1B - COORDINATION OF BENEFITS

Patient Support Program	Is the patient enrolled in any assistance program for the requested drug? ☐ Yes ☐ No			
	Program Name			Patient Identifier
	Contact First Name	Contact Last Name	Contact Phone	Contact Email
Drug Access Navigator	Is the patient in contact with an alternate drug access navigator (i.e., hospital)? ☐ Yes ☐ No			
	Organization Name			
	Contact First Name	Contact Last Name	Contact Phone	Contact Email
Provincial Coverage	Has the patient applied for reimbursement under a provincial plan? ☐ Yes ☐ No ☐ NA			
	What is the coverage decision? (Attach decision outcome letter) ☐ Approved ☐ Denied			
Other Private Coverage	Is this patient covered by any other plan? (If yes answer below) ☐ Yes ☐ No ☐ NA			
	Planholder First Name		Planholder Last Name	Date of Birth (YYYY/MM/DD)
	Relationship to Planholder ☐ Self ☐ Spouse ☐ Dependant ☐ Other _____			
	What is the coverage decision? (Attach outcome letter if received) ☐ Approved ☐ Denied			

SECTION 1C – CONSENT

I hereby authorize any licensed physician/dentist, medical practitioner, hospital, patient assistance program, clinic, or medically related facility to provide to Entente Plus information regarding my health as it relates to this request. I hereby authorize Entente Plus to obtain and exchange my personal information with other parties as required, including any health care provider, patient assistance program and/or Specialty Care Program vendor working with Entente Plus for the purpose of administering this benefit, and to any prescribed entity as defined by the Personal Health Information Protection Act, 2004, for analysis or statistical purposes related to managing, evaluating, or planning for all or part of the health system, including resource allocation and the delivery of health services. I acknowledge that my personal information is needed to assess eligibility for this drug, to administer the group benefits plan, and where applicable, to the Specialty Care Program and patient support services on my behalf. I acknowledge that my personal information may be exchanged and transferred between these parties for these purposes and may include information about my drug claims, diagnosis, medical condition, treatment, and other health related information. I acknowledge that providing my consent will help Entente Plus to assess my claim and that refusing to consent may result in delay or denial of my claim. This consent may be revoked by me at any time by sending written instructions to that effect at the address indicated below. I understand that personal information may be subject to disclosure to those authorized under applicable law within Canada only when the information is needed to administer this benefit and/or to confirm the accuracy of this information. I certify that the information given is true, correct, and complete to the best of my knowledge.

Signature of Patient	Date (YYYY/MM/DD)
-----------------------------	--------------------------

If under 16 years of age (14 years of age in Quebec), the signature of the parent / guardian is required.

**PRESCRIPTION DRUG SPECIAL AUTHORIZATION REQUEST FORM
SETMELANOTIDE (Imcivree)**

**Entente
Plus⁺**

SECTION 2A – DRUG REQUESTED FOR EVALUATION

Product Name and Strength	
Dose	Frequency of Administration
Route (ex. oral, IV, etc.)	Therapy Duration

Is the patient currently on the requested therapy? ☐ Yes ☐ No Therapy Start Date (Y/M/D)
(If yes provide therapy start date)

If already established on therapy, please attach proof of payment and details of prior coverage. Individuals established on therapy through compassionate coverage will only be considered if they met this plan's criteria on initiation of therapy.

SECTION 2B – LOCATION OF ADMINISTRATION

☐ Home ☐ Physician's Office ☐ Hospital (In-Patient) ☐ Hospital (Out-Patient) ☐ Infusion Center	For Infusion Centers please complete information below		
	Name and Address of Infusion Center		
	City	Province	Postal Code

SECTION 2C – DRUG REQUESTED FOR EVALUATION

Initial approval (6 months):

- ☐ For weight management in adult and pediatric patients 6 years of age and older with obesity* due to:
- Clinically or genetically confirmed Bardet-Biedl syndrome (BBS), OR
 - Genetically confirmed biallelic pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency due to variants interpreted as pathogenic, likely pathogenic, or of uncertain significance

Physician must be an endocrinologist, pediatric endocrinologist, and/or specialist in weight management or obesity.

*Clinical obesity is defined as BMI ≥ 30 kg/m² (for those ≥ 16 years) or weight > 97 th percentile for age and sex¹ on growth charts (for those aged 6 to 15 years).

¹Refers to sex assigned at birth.

Does the patient have Clinically or genetically confirmed Bardet-Biedl syndrome (BBS)?

☐ YES ☐ NO

Does the patient have genetically confirmed biallelic pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency due to variants interpreted as pathogenic, likely pathogenic, or of uncertain significance? ☐ YES ☐ NO

Physician is an endocrinologist, pediatric endocrinologist, and/or specialist in weight management or obesity

☐ YES ☐ NO

PRESCRIPTION DRUG SPECIAL AUTHORIZATION REQUEST FORM
SETMELANOTIDE (Imcivree)

Patient's age: _____

For patients 6 to 15 years of age, is weight over the 97th percentile for age and sex¹ on growth charts?

☐ YES ☐ NO

Date of current measurements: _____

Patient's current measurements:

Height (cm/in): _____ Weight (kg/lb): _____ BMI (kg/m²): _____

Renewal Criteria (12 months):

Subsequent renewals will only be considered for the following:

- Patients aged 18 and over if $\geq 5\%$ of body weight OR BMI was lost and maintained after initial treatment course.
- Patients aged 6 to 17 years of age if $\geq 5\%$ of BMI was lost and maintained after initial treatment course.

Patient's baseline and current height, weight, and body mass index(BMI) must be indicated.

Baseline measurements:

Date of baseline measurements: _____

Patient's baseline measurements:

Height (cm/in): _____ Weight (kg/lb): _____ BMI (kg/m²): _____

Current measurements:

Date of current measurements: _____

Patient's current measurements:

Height (cm/in): _____ Weight (kg/lb): _____ BMI (kg/m²): _____

PRESCRIPTION DRUG SPECIAL AUTHORIZATION REQUEST FORM

Please note: Incomplete information may delay your request for processing.

**Entente
Plus⁺****SECTION 3A – PRESCRIBER INFORMATION AND SIGNATURE**

First Name	License Number	Specialty
Last Name	Telephone	Fax
Street Address		
City	Province	Postal Code
Signature		Date (YYYY/MM/DD)

SECTION 3B – SUBMISSION INSTRUCTIONS

Return request form to:

Fax : 1-519-739-6483 or 1-866-797-6483	Mail: Entente Plus Drug Special Authorization Team, P.O BOX 1606, Windsor ON N9A 6W1
Email : drugspecial.autho@ententeplus.ca	

COST OF OBTAINING THIS INFORMATION IS AT THE EXPENSE OF THE PATIENT/PLAN MEMBER.